The stock price of Ranbaxy (OTC:RBXLY), subsidiary of Japan based Daiichi Sankyo (OTCPK:DSKYF) is up 30 percent over the last 3 months (as against 13.1% by other specialty generic companies) and I believe this is an opportune time for investors to cash in. The run up is in expectation of a turnaround driven by a few first to file (NYSEMKT:FTF) generic drug launches (Nexium and Valcyte generics) and upside from a strong ramp up of its acne drug Absorica (Isotretinoin) in the US. I believe there is over optimism surrounding the stock and it makes sense to exit,
· There is a strong chance that Ranbaxy may not be able to capitalize on these...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|